JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

CytoSorbents Corp

Fermé

SecteurSoins de santé

1.1 10

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.97

Max

1.18

Chiffres clés

By Trading Economics

Revenu

6.4M

-1.5M

Ventes

-423K

8.7M

Marge bénéficiaire

-16.94

Employés

149

EBITDA

8.1M

-468K

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.6M

57M

Ouverture précédente

-8.9

Clôture précédente

1.1

Sentiment de l'Actualité

By Acuity

46%

54%

151 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

CytoSorbents Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 août 2025, 17:49 UTC

Principaux Mouvements du Marché

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 août 2025, 17:18 UTC

Principaux Mouvements du Marché

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 août 2025, 16:25 UTC

Résultats

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 août 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 août 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 août 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 août 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 août 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 août 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 août 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 août 2025, 20:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 août 2025, 20:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 août 2025, 20:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement 2Q Rev $25.8M >EXOD

11 août 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 août 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 août 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 août 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 août 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 août 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 août 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 août 2025, 16:42 UTC

Acquisitions, Fusions, Rachats

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 août 2025, 16:27 UTC

Acquisitions, Fusions, Rachats

BBVA Says Sabadell Offer Remains in Effect

11 août 2025, 16:26 UTC

Acquisitions, Fusions, Rachats

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 août 2025, 16:25 UTC

Acquisitions, Fusions, Rachats

Banco de Sabadell Announced TSB Sale on July 1

11 août 2025, 16:25 UTC

Acquisitions, Fusions, Rachats

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparaison

Variation de prix

CytoSorbents Corp prévision

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

0.705 / 0.771Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

151 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.